News

Clinical Trials Arena on MSN16d
Omeros to activate site for Phase III programme of zaltenibart for PNH
Omeros has announced that the activation of clinical trial sites for patient enrolment is now in progress for its Phase III ...
Seeking Alpha19d
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
A total of 120 clinical investigative sites across 30 countries have been chosen for clinical trial participation in the zaltenibart Phase 3 program in PNH, a good number of which have already ...
Business Insider22d
Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche
EXTON, PA, March 18, 2025 (GLOBE NEWSWIRE) -- Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating blood disorder that affects approximately 8,000 to 10,000 people in North America ...
pharmaphorum6mon
Roche's PNH drug PiaSky backed for NHS use by NICE
Roche's PiaSky has been recommended for use by the NHS in England and Wales for the rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH), becoming the first option for patients that can ...
Business Insider19d
Omeros provides update on zaltenibart trial
A total of 120 clinical investigative sites across 30 countries have been chosen for clinical trial participation in the zaltenibart Phase 3 program in PNH, a good number of which have already ...
pharmaphorum1y
Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH
Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The drug ...
Nasdaq19d
Omeros Advances Zaltenibart Phase 3 Trials For PNH, Data Readout Expected In Late 2026
(RTTNews) - Omeros Corp. (OMER), Friday announced that it has initiated clinical trial site activation for its Phase 3 program evaluating zaltenibart or OMS906 in paroxysmal nocturnal ...